Abstract
We report here the 12-year survival after the first peptide receptor radionuclide therapy (PRRT) of a patient with metastatic rectal neuroendocrine neoplasms, who received 7 cycles of PRRT with Lu/Y-DOTATATE/DOTATOC in 4 treatment phases. The patient demonstrated excellent response to each cycle of treatment, without any adverse effect even after repeated PRRT cycles. Most recently, immunohistochemistry revealed a G3 neuroendocrine neoplasm and intraspinal metastasis were successfully resected by neurosurgical intervention. This case nicely demonstrates that several "salvage" PRRTs can be given over many years leading to repetitive benefit for the patient and saving patients of possible toxicity of alternative treatments.
MeSH terms
-
Adult
-
Bone Neoplasms / diagnostic imaging
-
Bone Neoplasms / radiotherapy
-
Bone Neoplasms / secondary*
-
Heart Neoplasms / diagnostic imaging
-
Heart Neoplasms / radiotherapy
-
Heart Neoplasms / secondary*
-
Humans
-
Lung Neoplasms / diagnostic imaging
-
Lung Neoplasms / radiotherapy
-
Lung Neoplasms / secondary*
-
Lymphatic Metastasis / diagnostic imaging
-
Lymphatic Metastasis / radiotherapy
-
Male
-
Neuroendocrine Tumors / diagnostic imaging
-
Neuroendocrine Tumors / pathology*
-
Neuroendocrine Tumors / radiotherapy
-
Octreotide / analogs & derivatives
-
Octreotide / therapeutic use
-
Organometallic Compounds / therapeutic use
-
Radiopharmaceuticals / therapeutic use
-
Radiotherapy / methods*
-
Rectal Neoplasms / diagnostic imaging
-
Rectal Neoplasms / pathology*
-
Rectal Neoplasms / radiotherapy
-
Salvage Therapy*
-
Treatment Outcome
Substances
-
Organometallic Compounds
-
Radiopharmaceuticals
-
90Y-octreotide, DOTA-Tyr(3)-
-
lutetium Lu 177 dotatate
-
Octreotide